| Autor: |
Chantal Baron, Samer Mansour, Denis-Claude Roy, Reda Salem, Louis-Mathieu Stevens, Nicolas Noiseux, Daiana Masckauchan, Jessica Forcillo, Eric Larose, Ignacio Prieto |
| Rok vydání: |
2013 |
| Předmět: |
|
| Zdroj: |
Canadian Journal of Cardiology. 29:441-447 |
| ISSN: |
0828-282X |
| DOI: |
10.1016/j.cjca.2012.08.009 |
| Popis: |
Background The Imp lantation of A utologous C D133 + S t em Cells in Patients Undergoing CABG (IMPACT-CABG) trial is investigating the feasibility, safety, and efficacy of intramyocardial injections of autologous CD133 + stem cells during coronary artery bypass grafting (CABG) in patients with chronic ischemic cardiomyopathy. We are reporting the results of the first 5 open-label patients. Methods Bone marrow was harvested from iliac crests and stem cells were isolated using the CliniMACS CD133 + Reagent System (Miltenyi Biotec, GmbH, Bergisch Gladbach, Germany). Patients received CABG, followed by CD133 + cellular injection in the revascularized hypokinetic myocardium. Results Five males New York Heart Association (NYHA) class III patients aged 64 ± 10 years were treated. Immunomagnetic cell processing allowed an average of 100 ± 48-fold enrichment in CD133 + cells, with 92 ± 11% recovery after selection. Mean number of CD133 + cells injected was 8.4 ± 1.2 million. There were no protocol-related complications during the 18-month follow-up and all patients improved to NYHA class I. Six-month echocardiography showed no significant improvement in left ventricular ejection fraction (34 ± 2% at baseline vs 38 ± 12%: P = 0.50). However, cardiac magnetic resonance showed that systolic wall thickening increased from 15.0 ± 10.5% to 29.0 ± 22.1% ( P = 0.01). In addition, mean segmental wall thickness also improved in comparison with baseline (10.7 ± 2.7% to 12.1 ± 4.8%; P Conclusions This work represents the first Canadian experience with CD133 + stem cells for the treatment of chronic ischemic cardiomyopathy. These results demonstrate the initial safety and feasibility of the IMPACT-CABG pilot trial. Subsequent patients are now being randomized to receive either CD133 + stem cell or placebo. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect